Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:46:14 EST Mon 15 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:DTCFF - DEFENCE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DTCFF - Qnot subscribed0.595233+0.0301335.364.737350.56  0.6196  0.561.1575  0.273215:05:47Dec 1115 min RT 2¢

Recent Trades - Last 10 of 35
Time ETExPriceChangeVolume
15:05:47Q0.5952330.0301332,000
14:53:30Q0.58010.0151,000
13:40:51Q0.597150.03205167
13:25:17Q0.5850.01991,500
12:45:13Q0.591940.02684333
11:13:04Q0.61960.05452,000
11:12:03Q0.590.02494,200
11:12:03Q0.590.0249172
11:12:03Q0.590.0249500
11:12:03Q0.590.02491,500

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-11 08:35U:DTCFFNews ReleaseDefence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th
2025-12-10 16:31U:DTCFFNews ReleaseDefence Therapeutics Announces AGM Results and Provides Corporate Updates
2025-12-04 03:17U:DTCFFNews ReleaseDefence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
2025-11-21 18:04U:DTCFFNews ReleaseDefence Therapeutics Announces Convertible Debenture Conversion
2025-11-19 03:16U:DTCFFNews ReleaseDefence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
2025-11-06 03:17U:DTCFFNews ReleaseDefence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
2025-11-04 03:16U:DTCFFNews ReleaseDefence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
2025-10-23 03:16U:DTCFFNews ReleaseDefence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
2025-10-06 03:16U:DTCFFNews ReleaseDefence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
2025-10-02 03:16U:DTCFFNews ReleaseDefence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
2025-09-23 09:16U:DTCFFNews ReleaseDefence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
2025-09-23 03:03U:DTCFFNews ReleaseEllis Martin Report: Dr. Amie Phinney of Defence Therapeutics Inc. (DTCFF) on the Accum(TM) Platform
2025-09-16 03:16U:DTCFFNews ReleaseDefence Therapeutics Appoints Dr. Amie Phinney as Director
2025-09-15 16:31U:DTCFFNews ReleaseDefence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
2025-09-02 03:16U:DTCFFNews ReleaseDefence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
2025-08-22 20:31U:DTCFFNews ReleaseDefence Therapeutics Announces Debenture Units Financing
2025-07-14 03:16U:DTCFFNews ReleaseDefence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer
2025-06-09 03:16U:DTCFFNews ReleaseDefence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
2025-06-02 03:16U:DTCFFNews ReleaseDefence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
2025-05-28 03:16U:DTCFFNews ReleaseDefence Therapeutics to Attend Bio International Convention in Boston, June 2025